These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 19243697

  • 21. Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
    Chowdhury MA, Abdellatif KR, Dong Y, Das D, Suresh MR, Knaus EE.
    Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6138-41. PubMed ID: 18945614
    [Abstract] [Full Text] [Related]

  • 22. Biological evaluation of 2-(4-amino-phenyl)-3-(3,5-dihydroxylphenyl) propenoic acid.
    Xu GL, Liu F, Zhao Y, Ao GZ, Xi L, Ju M, Xue T.
    Basic Clin Pharmacol Toxicol; 2009 Nov 01; 105(5):350-6. PubMed ID: 19744157
    [Abstract] [Full Text] [Related]

  • 23. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
    Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Grayson G, Komater V, Wilcox D, King L, Marsh K, Jarvis MF, Nuss M, Nellans H, Pruesser L, Reinhart GA, Cox B, Jacobson P, Stewart A, Coghlan M, Carter G, Bell RL.
    J Pharmacol Exp Ther; 2004 Dec 01; 311(3):904-12. PubMed ID: 15277581
    [Abstract] [Full Text] [Related]

  • 24. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
    Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ.
    Br J Pharmacol; 2005 Feb 01; 144(4):538-50. PubMed ID: 15655513
    [Abstract] [Full Text] [Related]

  • 25. Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
    Paredes Y, Massicotte F, Pelletier JP, Martel-Pelletier J, Laufer S, Lajeunesse D.
    Arthritis Rheum; 2002 Jul 01; 46(7):1804-12. PubMed ID: 12124864
    [Abstract] [Full Text] [Related]

  • 26. Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation.
    Schühly W, Hüfner A, Pferschy-Wenzig EM, Prettner E, Adams M, Bodensieck A, Kunert O, Oluwemimo A, Haslinger E, Bauer R.
    Bioorg Med Chem; 2009 Jul 01; 17(13):4459-65. PubMed ID: 19481465
    [Abstract] [Full Text] [Related]

  • 27. SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
    Griswold DE, Marshall PJ, Webb EF, Godfrey R, Newton J, DiMartino MJ, Sarau HM, Gleason JG, Poste G, Hanna N.
    Biochem Pharmacol; 1987 Oct 15; 36(20):3463-70. PubMed ID: 2823821
    [Abstract] [Full Text] [Related]

  • 28. Anti-inflammatory activity of Acanthus ilicifolius.
    Mani Senthil Kumar KT, Gorain B, Roy DK, Zothanpuia, Samanta SK, Pal M, Biswas P, Roy A, Adhikari D, Karmakar S, Sen T.
    J Ethnopharmacol; 2008 Oct 30; 120(1):7-12. PubMed ID: 18703126
    [Abstract] [Full Text] [Related]

  • 29. 3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
    Khanapure SP, Augustyniak ME, Earl RA, Garvey DS, Letts LG, Martino AM, Murty MG, Schwalb DJ, Shumway MJ, Trocha AM, Young DV, Zemtseva IS, Janero DR.
    J Med Chem; 2005 Jun 02; 48(11):3930-4. PubMed ID: 15916445
    [Abstract] [Full Text] [Related]

  • 30. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
    Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.
    J Pharmacol Exp Ther; 2005 Mar 02; 312(3):1206-12. PubMed ID: 15494548
    [Abstract] [Full Text] [Related]

  • 31. Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes.
    Lacerda RB, de Lima CK, da Silva LL, Romeiro NC, Miranda AL, Barreiro EJ, Fraga CA.
    Bioorg Med Chem; 2009 Jan 01; 17(1):74-84. PubMed ID: 19059783
    [Abstract] [Full Text] [Related]

  • 32. Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives.
    Li MH, Yin LL, Cai MJ, Zhang WY, Huang Y, Wang X, Zhu XZ, Shen JK.
    Acta Pharmacol Sin; 2005 Jul 01; 26(7):865-72. PubMed ID: 15960895
    [Abstract] [Full Text] [Related]

  • 33. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor.
    Imanishi J, Morita Y, Yoshimi E, Kuroda K, Masunaga T, Yamagami K, Kuno M, Hamachi E, Aoki S, Takahashi F, Nakamura K, Miyata S, Ohkubo Y, Mutoh S.
    Biochem Pharmacol; 2011 Oct 01; 82(7):746-54. PubMed ID: 21745460
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.
    Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J.
    Eur J Pharmacol; 2008 Jun 24; 588(1):93-8. PubMed ID: 18457826
    [Abstract] [Full Text] [Related]

  • 35. Pharmacological profile of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
    Hanna N, Marshall PJ, Newton J, Schwartz L, Kirsh R, Dimartino MJ, Adams J, Bender P, Griswold DE.
    Drugs Exp Clin Res; 1990 Jun 24; 16(4):137-47. PubMed ID: 2127565
    [Abstract] [Full Text] [Related]

  • 36. Derivatives of schisandrin with increased inhibitory potential on prostaglandin E(2) and leukotriene B(4) formation in vitro.
    Blunder M, Pferschy-Wenzig EM, Fabian WM, Hüfner A, Kunert O, Saf R, Schühly W, Bauer R.
    Bioorg Med Chem; 2010 Apr 01; 18(7):2809-15. PubMed ID: 20236826
    [Abstract] [Full Text] [Related]

  • 37. The influence of acetylshikonin, a natural naphthoquinone, on the production of leukotriene B4 and thromboxane A2 in rat neutrophils.
    Hsu MF, Chang LC, Huang LJ, Kuo SC, Lee HY, Lu MC, Wang JP.
    Eur J Pharmacol; 2009 Apr 01; 607(1-3):234-43. PubMed ID: 19232341
    [Abstract] [Full Text] [Related]

  • 38. Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors.
    Navidpour L, Shadnia H, Shafaroodi H, Amini M, Dehpour AR, Shafiee A.
    Bioorg Med Chem; 2007 Mar 01; 15(5):1976-82. PubMed ID: 17258905
    [Abstract] [Full Text] [Related]

  • 39. SKI306X, an oriental herbal mixture, suppresses gastric leukotriene B4 synthesis without causing mucosal injury and the diclofenac-induced gastric lesions.
    Kim JH, Rhee HI, Jung IH, Ryu K, Jung K, Han CK, Kwak WJ, Cho YB, Joo HJ.
    Life Sci; 2005 Jul 29; 77(11):1181-93. PubMed ID: 15935401
    [Abstract] [Full Text] [Related]

  • 40. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors.
    Huntjens DR, Spalding DJ, Danhof M, Della Pasqua OE.
    Eur J Pain; 2009 May 29; 13(5):448-57. PubMed ID: 18774319
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.